
A major genetic study challenges long-held assumptions about cerebral palsy.
New research is challenging how scientists understand cerebral palsy (CP). Of 515 genes previously linked to the condition, only 89 showed a statistically significant association in a new study, suggesting that many proposed genetic connections still lack sufficient evidence.
Published in the journal American Journal of Human Genetics, the research also proposes a different way to classify CP. Rather than treating it as a single disorder, the scientists suggest it may be better understood as a collection of symptoms arising from multiple underlying conditions.
Rethinking the Causes of Cerebral Palsy
Cerebral palsy is the most common motor disability in children, with up to 10,000 babies diagnosed in the United States annually. It has traditionally been associated with complications around birth, including premature delivery and temporary oxygen deprivation. However, genetic research over the past decade has increasingly pointed to inherited or newly occurring genetic variants as potential contributors. Unlike progressive neurological diseases, CP does not worsen over time, and rehabilitation and physical therapy can improve symptoms.
“There has been a lack of consensus on the definition of cerebral palsy and on the role of genetics in disease pathogenesis, leading to substantial variability in whether a child is diagnosed with CP,” says corresponding author Peter Robinson of the Jackson Laboratory for Genomic Medicine and the Berlin Institute of Health at Charité.
“We have developed a paradigm that considers CP to be a phenotypic trait rather than a precise disease diagnosis. A better understanding of specific genetic variants has the potential to improve our understanding of the biology of the disease.”
How Strong Is the Genetic Evidence?
To investigate the genetic basis of CP, the researchers evaluated evidence from 21 previously published studies involving 5,440 people diagnosed with the condition. These studies had identified potentially causal variants across hundreds of genes, but the new statistical analysis found convincing evidence of association for only a fraction of them.
“We decided to do this study because there has been no accepted statistical method to determine if a disease-associated gene is truly linked to CP,” says first author Adam Arterbery of the Jackson Laboratory for Genomic Medicine. “We discovered it was extremely difficult to find statistical evidence of causality for many of the genetic variants previously linked to CP.”
The team also performed whole-genome sequencing on 460 children from 453 families receiving care at Shriners Children’s hospitals across the United States. Pathogenic or likely pathogenic genetic variants were identified in 70 families, spanning 60 genes. However, just 16 of those genes overlapped with the genes supported by statistically significant evidence in the analysis of earlier studies.
A Different Framework for Diagnosis and Treatment
The researchers emphasize that their findings do not disprove connections between CP and the remaining genes. Instead, the available data are insufficient to establish those associations with statistical confidence. They propose viewing CP as a clinical characteristic that can emerge from different genetic disorders and environmental influences, rather than a single disease with a common biological origin.
“This framework could improve interpretation of genomic testing, help identify children who may warrant closer CP surveillance or specialist referral, and potentially identify genetic conditions requiring disease-specific management,” Robinson says. “But clinical utility and patient benefit will absolutely need validation before these findings can be applied to patient care.”
Future studies will focus on larger patient populations, prospective evaluations of clinical benefits and costs, and better access to genomic and medical data. “We hope our study will stimulate discussion about CP terminology, gene-disease associations, and variant interpretation,” Arterbery says. “The most productive response will be further validation and development of better genotype-phenotype evidence rather than treating the findings as a definitive list of CP genes.”
Reference: “A phenotypic paradigm for cerebral palsy genetics” by Adam S. Arterbery, Michael A. Gargano, Anita Bagley, Jagadish Chandrabose Sundaramurthi, Lauren Rekerle, Thania Ordaz-Robles, Daniel Danis, Adam S.L. Graefe, Ana L. Arenas-Díaz, Jeremy P. Bauer, Hannah Blau, Leigh Carmody, Kristen I. Carroll, Janice Davis, Philip F. Giampietro, Anxhela Gjyshi Gustafson, Monserat Hernandez, Julius O.B. Jacobsen, Paige Lemhouse, David Millet, Shubhra Mukherjee, Patrick S. Nairne, Emily Nice, Talia Plotkin, Kenneth Powell, Lukas Ramlow, Ellen M. Raney, Mallory Shingle, Damian Smedley, Peter A. Smith, Demiana A. Soliman, David E. Westberry, Jon R. Davids and Peter N. Robinson, 3 September 2026, The American Journal of Human Genetics.
DOI: 10.1016/j.ajhg.2026.08.007
This work was supported by Shriners Children’s, the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Human Genome Research Institute, and the Alexander von Humboldt Foundation.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.